Gemini Therapeutics, Inc. /DE: management transactions · United States · SEC (Form 4)

About Gemini Therapeutics, Inc. /DE

Gemini Therapeutics, Inc. /DE was a U.S.-based biopharmaceutical company originally built around precision medicine for ophthalmology, with a particular focus on age-related macular degeneration (AMD). The company emerged in Cambridge, Massachusetts, within one of the strongest biotech clusters in the United States. Its development strategy centered on genetically and biologically defined patient subsets, using a translational approach tied to complement biology and retinal disease mechanisms. Gemini’s lead asset was GEM103, a program advanced for dry AMD, which gave the company a niche position in the retinal disease landscape and differentiated it from broader ophthalmology developers. ([nasdaq.com](https://www.nasdaq.com/press-release/gemini-therapeutics-announces-presentation-of-preclinical-data-at-the-13th?utm_source=openai)) From an investor perspective, Gemini was a classic venture-backed clinical-stage biotech: research-intensive, capital-dependent, and highly reliant on clinical readouts and regulatory execution. Public filings and contemporaneous company materials indicate that the business was still in development mode, without meaningful product revenue, and with value creation tied almost entirely to advancing pipeline assets through clinical development. That profile typically implies high upside optionality, but also elevated binary risk, long commercialization timelines, and continued financing needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1816736/000095017024034432/iron-20231231.htm?utm_source=openai)) A major corporate turning point came in 2022, when Gemini announced a merger agreement with Disc Medicine. The transaction closed on December 29, 2022. Following completion, Gemini Therapeutics ceased to exist as a standalone public issuer; the combined company was renamed Disc Medicine, Inc. and its common stock began trading on the Nasdaq Capital Market under the symbol IRON. In other words, while Gemini is still relevant for historical SEC filings, it is no longer an independent listed operating company. ([nasdaq.com](https://www.nasdaq.com/press-release/disc-medicine-announces-completion-of-merger-with-gemini-therapeutics-2022-12-29?utm_source=openai)) For a French, Belgian, or Swiss investor reviewing Gemini-related Form 4 activity, the key analytical point is to separate legacy Gemini disclosures from the current public-equity story. The company was incorporated in Delaware in the United States and traded on the U.S. Nasdaq market during its life as an independent issuer, but its corporate footprint was effectively absorbed into Disc Medicine after the merger. That means the legacy Gemini thesis should be read as a historical biotech ophtalmology program, not as an ongoing stand-alone investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/95017022003288/0000950170-22-003288-index.html?utm_source=openai))